- This event has passed.
Crossing the Valley of Death: Lab to IPO & Lab to Acquisition – Hosted by ABCT
November 30, 2021 @ 1:00 pm - 2:30 pm
Join our experienced panelists to learn about crossing into the business world in Part 3 of our Valley of Death workshop series!
Join us online November 30th, to hear Ke Cheng, CEO and founder HistoWiz, ELab alum ’13 and Matthew Meyer, former Chief Business officer CAREDx and now Chief Buisness Advisor Wilson Sonsini, as they share their journeys crossing the chasm to lead ventures from academia to partnerships, major funding rounds and acquisitions.
Immediately following the Q&A portion of the panel, you’ll have an opportunity to meet and talk with our speakers at virtual tables. Get to know more about them below!
Speakers:
Ke Cheng, PhD is the founder and CEO of HistoWiz and is an ELabNYC Alumni of 2013.
Ke has over 10 years of experience in mouse histopathology and cancer research. She finished her Ph.D. in Cancer Biology from Pier Paolo Pandolfi’s lab at Harvard and led a team of investigators to publish papers in journals such as Nature and Blood. Prior to founding HistoWiz, she worked at a cancer diagnostics company (NASDAQ: CGIX) and did a postdoctoral fellowship with Douglas Hanahan at the Swiss Institute of Experimental Cancer Research. Ke is actively involved in the NYC bioscience community and plays water polo in her free time.
Matthew J. Meyer is chief business advisor for life sciences at Wilson Sonsini. Matthew leads the firm’s life science business advisory practice—a newly formed, innovative resource aimed at providing start-up and emerging life sciences companies with business insights, capabilities, and strategies to help them thrive and address some of their most challenging issues.
Matthew is an experienced executive and attorney who has held diverse roles of increasing responsibility across a wide range of private and public biopharma, medtech, and precision medicine companies from start-ups to Fortune 50 in the U.S. and Europe, including Pfizer, Novartis, and CareDx. His leadership capabilities include delivery of strong commercial results, structuring and executing partnering transactions across the product life cycle, raising debt and equity capital in the private and public markets, and working with founders, management teams, and boards to address complex business issues to support rapid growth.